8-K: HeartBeam Appoints Timothy Cruickshank as New Chief Financial Officer

HeartBeam, Inc. has appointed Timothy Cruickshank as its new Chief Financial Officer, effective September 9, 2024.

Summary

• HeartBeam, Inc. has appointed Timothy Cruickshank as its new Chief Financial Officer, effective September 9, 2024.
• Mr. Cruickshank's employment agreement includes an annual salary of $385,000, paid semi-monthly.
• He is also eligible for an incentive bonus of up to 45% of his base salary, based on corporate goals.
• Subject to board approval, Mr. Cruickshank will receive an option to purchase 400,000 shares of the company's common stock.
• Mr. Cruickshank previously served as CFO of ImpediMed from October 2019 to March 2024, where he helped transition the company to a SaaS business model.
• The company issued a press release on September 10, 2024, announcing the appointment.

Sentiment

Score: 8

Explanation: The appointment of an experienced CFO is a positive development for the company, suggesting a focus on financial stability and growth. The terms of the employment agreement are standard and the management comments are optimistic.

Positives

• The appointment of Timothy Cruickshank brings a seasoned financial executive with over 15 years of public company experience to HeartBeam.
• Mr. Cruickshank has a proven track record of strategic planning and financial stewardship, including experience in transitioning a medical device company to a SaaS model.
• The incentive bonus structure for the CFO is tied to corporate goals, aligning his interests with the company's success.
• The grant of stock options provides a long term incentive for the new CFO.
• The company has a strong financial foundation established by the previous CFO.

Risks

• The company's first 510(k) submission is currently under review with the FDA, and there is no guarantee of approval.
• The company is in a growth phase and will need to manage its finances carefully to achieve its goals.
• The company is reliant on the success of its technology and its ability to commercialize it.

Future Outlook

The company aims to commercialize its technology, drive financial excellence, and expand its impact to improve cardiac care for patients.

Management Comments

• Branislav Vajdic, CEO of HeartBeam, stated that Tim has an outstanding record of delivering results and creating value.
• Mr. Vajdic also mentioned that Mr. Cruickshank will be a strong partner in ensuring the company has a solid financial position.
• Timothy Cruickshank said he is excited to join the company at this pivotal time and looks forward to working with the team to commercialize the technology.

Industry Context

The appointment of a seasoned CFO with experience in transitioning to a SaaS model aligns with the broader trend of medical technology companies leveraging software and digital platforms for growth and recurring revenue.

Comparison to Industry Standards

• The compensation package for the CFO, including a base salary of $385,000 and a 45% bonus target, is within the typical range for a public company CFO in the medical technology sector.
• The grant of 400,000 stock options is a common practice to incentivize executive performance and align their interests with shareholders.
• ImpediMed, where Mr. Cruickshank previously served as CFO, is a comparable medical technology company that has successfully launched a SaaS platform, SOZO, which is a positive indicator of his experience.
• Other companies in the medical device and digital health space, such as Masimo and Livongo, have also focused on integrating software and data analytics into their offerings, making Mr. Cruickshank's experience relevant to HeartBeam's strategic direction.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO as a positive sign for the company's future financial management and growth.
• Employees may benefit from the leadership and experience of the new CFO.
• Customers may see the company as more stable and reliable with a strong financial foundation.
• Suppliers and creditors may have increased confidence in the company's ability to meet its obligations.

Next Steps

• The Board of Directors needs to approve the stock option grant to Mr. Cruickshank.
• Mr. Cruickshank will begin his role as CFO on September 9, 2024.
• The company will continue to work on its 510(k) submission with the FDA.

Key Dates

Keywords

Chief Financial Officer, CFO, Timothy Cruickshank, HeartBeam, Medical Technology, Financial Executive, Stock Options, Incentive Bonus, FDA 510(k), SaaS